23.03 USD
+0.09 (+0.39%)
22.8148 USD
-0.22 (-0.93%)
We assign a fundamental rating of 5 out of 10 to AVDL. AVDL was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AVDL as it has an excellent financial health rating, but there are worries on the profitability. AVDL is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
AVDL had negative earnings in the past year.
AVDL had a positive operating cash flow in the past year.
AVDL had negative earnings in 4 of the past 5 years.
AVDL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AVDL has a Return On Assets of -0.14%. This is in the better half of the industry: AVDL outperforms 77.60% of its industry peers.
AVDL's Return On Equity of -0.28% is fine compared to the rest of the industry. AVDL outperforms 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROIC | N/A |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVDL has a Gross Margin of 91.09%. This is amongst the best in the industry. AVDL outperforms 93.23% of its industry peers.
AVDL's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVDL has more shares outstanding
Compared to 5 years ago, AVDL has more shares outstanding
The debt/assets ratio for AVDL is higher compared to a year ago.
2.2 Solvency
AVDL has an Altman-Z score of 8.65. This indicates that AVDL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.65, AVDL belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
AVDL has a better Debt to FCF ratio (1.80) than 93.75% of its industry peers.
AVDL has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
AVDL's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. AVDL outperforms 42.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Altman-Z | 8.65 |
ROIC/WACCN/A
WACC7.79%
2.3 Liquidity
AVDL has a Current Ratio of 2.76. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
AVDL has a Current ratio of 2.76. This is comparable to the rest of the industry: AVDL outperforms 48.44% of its industry peers.
A Quick Ratio of 2.37 indicates that AVDL has no problem at all paying its short term obligations.
With a Quick ratio value of 2.37, AVDL perfoms like the industry average, outperforming 47.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 100.00% over the past year.
The Revenue has grown by 79.88% in the past year. This is a very strong growth!
AVDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.35% yearly.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
3.2 Future
Based on estimates for the next years, AVDL will show a very strong growth in Earnings Per Share. The EPS will grow by 43.35% on average per year.
Based on estimates for the next years, AVDL will show a very strong growth in Revenue. The Revenue will grow by 25.45% on average per year.
EPS Next Y143.89%
EPS Next 2Y86.78%
EPS Next 3Y62.3%
EPS Next 5Y43.35%
Revenue Next Year61.36%
Revenue Next 2Y45.28%
Revenue Next 3Y37.74%
Revenue Next 5Y25.45%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Forward Earnings ratio is 29.75, which means the current valuation is very expensive for AVDL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVDL indicates a somewhat cheap valuation: AVDL is cheaper than 72.92% of the companies listed in the same industry.
AVDL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 29.75 |
4.2 Price Multiples
75.00% of the companies in the same industry are more expensive than AVDL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 107.79 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 62.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y86.78%
EPS Next 3Y62.3%
5. Dividend
5.1 Amount
No dividends for AVDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.03
+0.09 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners85.64%
Inst Owner Change-11.95%
Ins Owners4.89%
Ins Owner Change8.1%
Market Cap2.09B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target20.97 (-8.94%)
Short Float %8.92%
Short Ratio2.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.76%
PT rev (3m)7.48%
EPS NQ rev (1m)-10%
EPS NQ rev (3m)-16%
EPS NY rev (1m)-0.8%
EPS NY rev (3m)-5.65%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 29.75 | ||
| P/S | 8.39 | ||
| P/FCF | 107.79 | ||
| P/OCF | 60.39 | ||
| P/B | 21.24 | ||
| P/tB | 25.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.77
Fwd EY3.36%
FCF(TTM)0.21
FCFY0.93%
OCF(TTM)0.38
OCFY1.66%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% | ||
| FCFM | 7.79% |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 | ||
| Altman-Z | 8.65 |
F-Score4
WACC7.79%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y143.89%
EPS Next 2Y86.78%
EPS Next 3Y62.3%
EPS Next 5Y43.35%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year61.36%
Revenue Next 2Y45.28%
Revenue Next 3Y37.74%
Revenue Next 5Y25.45%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year180.96%
EBIT Next 3Y93.78%
EBIT Next 5Y44.74%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A
AVADEL PHARMACEUTICALS / AVDL FAQ
Can you provide the ChartMill fundamental rating for AVADEL PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 5 / 10 to AVDL.
Can you provide the valuation status for AVADEL PHARMACEUTICALS?
ChartMill assigns a valuation rating of 4 / 10 to AVADEL PHARMACEUTICALS (AVDL). This can be considered as Fairly Valued.
How profitable is AVADEL PHARMACEUTICALS (AVDL) stock?
AVADEL PHARMACEUTICALS (AVDL) has a profitability rating of 3 / 10.
What is the expected EPS growth for AVADEL PHARMACEUTICALS (AVDL) stock?
The Earnings per Share (EPS) of AVADEL PHARMACEUTICALS (AVDL) is expected to grow by 143.89% in the next year.